Physician profile
Megan E Mclean
NPI 1154779106
$2,638.28
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $949 · 2023: $406 · 2024: $77.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.84 | 2021-2023 | |
| Lilly USA, LLC | $327.98 | 2021-2022 | |
| Abbott Laboratories | $236.10 | 2022-2024 | Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $206.86 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $126.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $110.07 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.98 | 2021-2022 | |
| Amgen INC. | $94.80 | 2021-2022 | |
| Almatica Pharma LLC | $81.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $81.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $78.77 | 2021-2022 | |
| Allergan, INC. | $75.06 | 2021-2022 | |
| Astellas Pharma US INC | $67.36 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.89 | 2021-2022 | |
| Abiomed | $43.69 | 2024 | Impella |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $32.07 | 2023 | Doc Band |
| Kaleo, INC. | $30.29 | 2021-2022 | |
| Genentech USA, INC. | $29.86 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.53 | 2022 | |
| Medtronic, INC. | $20.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.